ANTX logo

AN2 Therapeutics (ANTX) Company Overview

Profile

Full Name:

AN2 Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 25, 2022

Indexes:

Not included

Description:

ANTX, or AN2 Therapeutics, focuses on developing innovative treatments for serious viral infections. The company aims to improve patient outcomes through advanced therapies, targeting unmet medical needs in infectious diseases. Their research emphasizes safety and effectiveness, contributing to better health solutions for patients worldwide.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 3, 25 JMP Securities
Market Outperform
Nov 19, 24 JMP Securities
Market Outperform
Nov 18, 24 TD Cowen
Hold
Aug 9, 24 JMP Securities
Market Outperform
Jul 3, 24 Leerink Partners
Outperform
May 16, 24 Evercore ISI Group
In-Line
Apr 2, 24 JMP Securities
Market Outperform
Apr 1, 24 Oppenheimer
Perform
Feb 13, 24 Leerink Partners
Market Perform
Feb 12, 24 Oppenheimer
Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for AN2 Therapeutics?
  • Does AN2 Therapeutics pay dividends?
  • What sector is AN2 Therapeutics in?
  • What industry is AN2 Therapeutics in?
  • What country is AN2 Therapeutics based in?
  • When did AN2 Therapeutics go public?
  • Is AN2 Therapeutics in the S&P 500?
  • Is AN2 Therapeutics in the NASDAQ 100?
  • Is AN2 Therapeutics in the Dow Jones?
  • When was AN2 Therapeutics's last earnings report?
  • When does AN2 Therapeutics report earnings?
  • Should I buy AN2 Therapeutics stock now?

What is the ticker symbol for AN2 Therapeutics?

The ticker symbol for AN2 Therapeutics is NASDAQ:ANTX

Does AN2 Therapeutics pay dividends?

No, AN2 Therapeutics does not pay dividends

What sector is AN2 Therapeutics in?

AN2 Therapeutics is in the Healthcare sector

What industry is AN2 Therapeutics in?

AN2 Therapeutics is in the Biotechnology industry

What country is AN2 Therapeutics based in?

AN2 Therapeutics is headquartered in United States

When did AN2 Therapeutics go public?

AN2 Therapeutics's initial public offering (IPO) was on March 25, 2022

Is AN2 Therapeutics in the S&P 500?

No, AN2 Therapeutics is not included in the S&P 500 index

Is AN2 Therapeutics in the NASDAQ 100?

No, AN2 Therapeutics is not included in the NASDAQ 100 index

Is AN2 Therapeutics in the Dow Jones?

No, AN2 Therapeutics is not included in the Dow Jones index

When was AN2 Therapeutics's last earnings report?

AN2 Therapeutics's most recent earnings report was on Nov 13, 2024

When does AN2 Therapeutics report earnings?

The next expected earnings date for AN2 Therapeutics is Mar 28, 2025

Should I buy AN2 Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions